Search results for " market"
Article
A Diverse Landscape of Patent Issues Seen in the US, UK, and the EU
In the EU, the market approval of a generic or biosimilar drug is not dependent on the patent status of its branded equivalent. Consequently, generic and biosimilar companies are able to launch "at ri…
Article
The Good and Bad of Biosimilars
Today, however, the competition is really beginning to heat up, with a rising tide of new biosimilar approvals coming from both established companies and new players, including companies in emerging m…
Article
Supply Chain Challenges for Single-Use Systems
Most SUS are currently made in the United States and the European Union, but suppliers are exploring manufacturing of SUS components in Asia to serve the region’s growing biopharma market more efficie…
Article
Fifteen Years of Progress: Biopharmaceutical Industry Survey Results
Today, many Chinese companies are expanding through biosimilars, contract manufacturing organization (CMO) partnering, and other means to reach Western markets. For example, China’s WuXi Biologics, a …
Article
Reducing Cross-Contamination Risks in Process Chromatography
…tment needs with respect to facility, equipment, and labor, enabling cost savings and faster time to market,” he says. All of the attributes of single-use technologies--reduced process time, faster e…
Article
Witnessing Major Growth in Next-Generation Antibodies
The global market for next-generation antibodies, including antibody drug conjugates (ADCs), engineered antibodies, bispecific antibodies, antibody fragments, antibody-like proteins and biosimilar ant…
Article
Efforts Accelerate to Streamline Postapproval Change Process
By Jill Wechsler
Frequent revisions and updates in manufacturing processes and operations are routine after a drug comes to market to improve products and systems and ensure reliable supply of hig…
Article
Platform Approach Speeds Process Development
The most preferred host cell line is the CHO cell, but other cell types such as the murine myeloma cells (NS0 and Sp2/0) are also still used, mainly for marketed products. For manufacturing of biophar…
Article
A Risk-Based Genetic Characterization Strategy for Recombinant CHO Cell Lines Used for Clinical and Commercial Applications
…at the limit for in vitro cell age harvested from the commercial cell-culture process to support the marketing authorization applications. Together, the presented strategy is integrated with other ex…
Article
Innovative Therapies Require Modern Manufacturing Systems
More biosimilars are poised to come to market in 2016 following FDA approval of the first such therapy in 2015. At the same time, though, the development of such innovative and targeted therapies heig…